TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38679140

Group type: EXPERIMENTAL
Intervention: Telephone-delivered motivational interviewing (MI) engagement session and 8 sessions of MI-Cognitive Behavioral Therapy (MI-CBT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) involving AUD psychoeducation, advice to reduce drinking and seek treatment, and provision of community resources
Number of subjects: 300
Study: 38679189

Group type: EXPERIMENTAL
Intervention: Interruptive EHR message during eligible patients' visits facilitating referral to the pharmacy service (Trial #1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automatic referral to centralized pharmacy services via a referral order placed in PCPs EHR inboxes for co-signature (Trial #2)
Number of subjects: 0
Study: 38679416

Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy under local anaesthesia (LA) using 40 mL 1% lidocaine with 4 mL of 8.4% sodium bicarbonate.
Number of subjects: 402
Study: 38679419

Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38679697

Group type: EXPERIMENTAL
Intervention: Complex intervention promoting deprescribing of antidepressants
Number of subjects: 12
Study: 38679727

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38680067

Group type: EXPERIMENTAL
Intervention: 14-day tailored PCR-guided triple therapy (esomeprazole 40 mg, amoxicillin 1000 mg b.d., clarithromycin 500 mg or levofloxacin 500 mg b.d.)
Number of subjects: 241

Group type: COMPARATOR
Intervention: 14-day non-Bismuth concomitant quadruple therapy (esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg b.d.)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: 14-day tailored PCR-guided triple therapy
Number of subjects: 241

Group type: COMPARATOR
Intervention: 14-day non-Bismuth concomitant quadruple therapy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Economic analysis of tailored PCR-guided triple therapy
Number of subjects: 241
Study: 38680485

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 38680516

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 226
Study: 38680993

Group type: EXPERIMENTAL
Intervention: Circulating regulatory T cells (Tregs)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mitochondrial respiration to glycolysis ratio (OCR/ECAR) in PBMCs
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 65
Study: 38681143

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 38681788

Group type: EXPERIMENTAL
Intervention: High-flow oxygen treatment (HFOT) through tracheostomy
Number of subjects: 11

Group type: COMPARATOR
Intervention: T-piece oxygen delivery
Number of subjects: 11
Study: 38681971

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 21374
Study: 38682103

Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Tunneled-cuffed catheters (TCC)
Number of subjects: 153
Study: 38682205

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt enriched with Platelet-Activating Factor receptor (PAF-R) antagonists (150 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain yogurt (control)
Number of subjects: 0
Study: 38682335

Group type: EXPERIMENTAL
Intervention: High-dose lipid-lowering therapy (atorvastatin ≥40 mg or equivalent)
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: Conventional doses of lipid-lowering therapy
Number of subjects: 2258

Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 2258

Group type: EXPERIMENTAL
Intervention: High-intensity lipid-lowering therapy
Number of subjects: 2258

Group type: COMPARATOR
Intervention: No statins
Number of subjects: 2258
Study: 38682459

Group type: EXPERIMENTAL
Intervention: Immediate and robust low-density lipoprotein cholesterol (LDL-C) reduction after acute coronary syndrome (ACS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early proprotein convertase subtilisin/kexin 9 inhibitor use after ACS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging therapeutic avenues such as bempedoic acid, lipoprotein(a) inhibition, ApoC3 modulation, and angiopoietin-like protein 3 targeting
Number of subjects: 0
Study: 38682560

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Number of subjects: 113
Study: 38682569

Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 20071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20071
Study: 38682750

Group type: EXPERIMENTAL
Intervention: EBV-seropositive donor and EBV-naïve recipient (D+R-)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: D+R-
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Monomorphic/polymorphic PTLD (n=21)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Non-liver transplant recipients with monomorphic/polymorphic PTLD
Number of subjects: 944
Study: 38682758

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (brief interventions ranging from a single session of 10 to 60 minutes to five sessions of 10 minutes each)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) or similar treatments (comprehensive assessment of alcohol use and advice to stop drinking during pregnancy)
Number of subjects: 1369
Study: 38682786

Group type: COMPARATOR
Intervention: ACE inhibitors (ACEi)
Number of subjects: 28341

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 28341

Group type: COMPARATOR
Intervention: ARB
Number of subjects: 28341
Study: 38682903

Group type: EXPERIMENTAL
Intervention: Modified Southwestern Aneurysm Severity Index (mSASI) model
Number of subjects: 242
Study: 38683027

Group type: EXPERIMENTAL
Intervention: Crushed 200-mg cenobamate tablet administered orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crushed 200-mg cenobamate tablet administered via nasogastric tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact 200-mg cenobamate tablet
Number of subjects: 0
Study: 38683145

Group type: EXPERIMENTAL
Intervention: MP0533 (multispecific CD3-engaging DARPin)
Number of subjects: 0
Study: 38683158

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulse oximetry plus clinical decision support algorithms (CDSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-post study in Kenya and Senegal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study: 38683439

Group type: EXPERIMENTAL
Intervention: EUROIA scale
Number of subjects: 231

Group type: COMPARATOR
Intervention: KCCQ-OS
Number of subjects: 231
Study: 38683479

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 1789

Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1789
Study: 38683495

Group type: EXPERIMENTAL
Intervention: MEDI7247
Number of subjects: 67
Study: 38683596

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily for 5 years
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Placebo once daily for 5 years
Number of subjects: 3020
Study: 38683602

Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 38683612

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 48
Study: 38683663

Group type: EXPERIMENTAL
Intervention: 6-month blended refresher training (Mixed6 group)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: 6-month traditional refresher training (Traditional6 group)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: 12-month blended refresher training (Mixed12 group)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: 6-month blended refresher training (Blended6 group)
Number of subjects: 1163
Study: 38683665

Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention with Bluetooth-connected monitoring devices and feedback system (n=39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group with conventional non-Bluetooth devices (n=38)
Number of subjects: 77
Study: 38683966

Group type: EXPERIMENTAL
Intervention: HA-1 TCR-T therapy after lymphodepleting chemotherapy
Number of subjects: 9
Study: 38684039

Group type: EXPERIMENTAL
Intervention: Unesbulin 300 mg administered orally twice per week plus DTIC 1,000 mg/m
Number of subjects: 0
Study: 38684046

Group type: EXPERIMENTAL
Intervention: Dutasteride 1 mg daily for 12 weeks
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 38684080

Group type: EXPERIMENTAL
Intervention: Patient partnership tools including a 1-page visit preparation guide and a library of short educational videos on medication safety.
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual care during control periods.
Number of subjects: 405
Study: 38684089

Group type: EXPERIMENTAL
Intervention: Marital self-disclosure intervention (4 phases, face-to-face)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 38684193

Group type: EXPERIMENTAL
Intervention: Traction-assisted endoscopic submucosal dissection (ESD)
Number of subjects: 106
Study: 38684230

Group type: EXPERIMENTAL
Intervention: MYTX-011
Number of subjects: 0
Study: 38684243

Group type: EXPERIMENTAL
Intervention: Norepinephrine (dilution to 0.016 mg/mL) using an electric syringe pump at a rate of 0.48 mg/h (30 mL/h) from the start of anaesthesia, titrated to achieve haemodynamic target.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Ephedrine, manual titration with a maximal dose of 30 mg, followed by perfusion with norepinephrine.
Number of subjects: 500
Study: 38684260

Group type: EXPERIMENTAL
Intervention: Maternal nightly positional therapy (PT)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Sham positional therapy (sham-PT)
Number of subjects: 167
Study: 38684265

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (oral Vitamin D3 50,000 IU/week for 4 weeks, then 50,000 IU once every 2 weeks for 52 weeks)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 38684276

Group type: EXPERIMENTAL
Intervention: Voluntary stopping eating and drinking (VSED)
Number of subjects: 37500

Group type: EXPERIMENTAL
Intervention: Independently taking lethal medication attended by a confidant (ILMC)
Number of subjects: 37500
Study: 38684277

Group type: EXPERIMENTAL
Intervention: CMNT diet with specific meal replacement Chinese medicinal foods (6 cycles of 5 consecutive days followed by 10 days of regular food intake)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care group with standard dietary advice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CMNT diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 120
Study: 38684558

Group type: EXPERIMENTAL
Intervention: Pictorial risk communication intervention
Number of subjects: 512
Study: 38684631

Group type: EXPERIMENTAL
Intervention: Lovo-cel gene therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common care
Number of subjects: 0
Study: 38684670

Group type: EXPERIMENTAL
Intervention: Intensive treatment regimen for high-risk SMM patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intensive treatment regimen for ultra-high risk (UHR) SMM patients
Number of subjects: 57
Study: 38684860

Group type: EXPERIMENTAL
Intervention: AI-enabled electrocardiogram (ECG) alert intervention
Number of subjects: 15965

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15965

Group type: EXPERIMENTAL
Intervention: AI-enabled ECG alert intervention in patients with high-risk ECGs
Number of subjects: 15965

Group type: COMPARATOR
Intervention: Control group for high-risk ECGs
Number of subjects: 15965
Study: 38684918

Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 148
Study: 38684956

Group type: COMPARATOR
Intervention: Cerebellar deep brain stimulation (DBS) in the dorsal dentate nucleus, using Medtronic Percept neurostimulator, with effective stimulation for one month followed by sham stimulation for one month in a random order.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation (control group) for one month followed by effective stimulation for one month in a random order.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerebellar DBS
Number of subjects: 10
Study: 38685016

Group type: EXPERIMENTAL
Intervention: AKL-T01
Number of subjects: 479
Study: 38685017

Group type: EXPERIMENTAL
Intervention: Outpatient Parenteral Antimicrobial Therapy (OPAT)
Number of subjects: 58
Study: 38685032

Group type: EXPERIMENTAL
Intervention: HPI-guided hemodynamic management using the Hemosphere platform and AcumenIQ® sensor (Edwards Lifesciences)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPI-guided hemodynamic management
Number of subjects: 0
Study: 38685042

Group type: EXPERIMENTAL
Intervention: Marfan syndrome (MFS) group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Matched healthy children
Number of subjects: 63
Study: 38685109

Group type: EXPERIMENTAL
Intervention: MMS for 180 days with one 180-count tablet bottle (MMS-180)
Number of subjects: 1545

Group type: COMPARATOR
Intervention: IFA for 90 days (IFA-90)
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: MMS for 180 days with two distributions of 90-count tablet bottles (MMS-90)
Number of subjects: 1545
Study: 38685119

Group type: EXPERIMENTAL
Intervention: Women with dense breasts (n=647)
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: All women surveyed (n=969)
Number of subjects: 969

Group type: COMPARATOR
Intervention: Women with non-dense breasts vs. dense breasts
Number of subjects: 969

Group type: COMPARATOR
Intervention: Women receiving chemotherapy
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Women who previously delayed breast cancer treatment more than 3 months
Number of subjects: 969
Study: 38685123

Group type: EXPERIMENTAL
Intervention: Miracle Friends
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Miracle Money
Number of subjects: 760

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 760
Study: 38685291

Group type: EXPERIMENTAL
Intervention: Graded Activity and Pain Education (GAPE)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 144
Study: 38685376

Group type: EXPERIMENTAL
Intervention: Neuroprognostication guidelines adherence
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Withdrawal of life-sustaining therapies (WLST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multimodal testing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clinical gestalt
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Objective diagnostics
Number of subjects: 30
Study: 38685400

Group type: EXPERIMENTAL
Intervention: Total diet replacement (TDR) with low-energy nutritionally complete formula products for 12 weeks and behavioural support
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study: 38685464

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1145
Study: 38685481

Group type: EXPERIMENTAL
Intervention: 2-g out-of-hospital TXA bolus
Number of subjects: 541

Group type: COMPARATOR
Intervention: 1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion
Number of subjects: 541

Group type: COMPARATOR
Intervention: Out-of-hospital saline bolus/in-hospital saline infusion (placebo)
Number of subjects: 541
Study: 38685704

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by four titanium-zirconium mini implants
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Flapless protocol
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Less resorbed ridges
Number of subjects: 74
Study: 38685855

Group type: EXPERIMENTAL
Intervention: Presence of life stressors
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Stressors with greater severity
Number of subjects: 81

Group type: COMPARATOR
Intervention: Absence of life stressors
Number of subjects: 81
Study: 38685868

Group type: EXPERIMENTAL
Intervention: Omission of sentinel lymph node biopsy (SLNB) after breast-conserving surgery (BCS) in patients showing BpCR after NACT.
Number of subjects: 178
Study: 38685922

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intensive non-surgical treatment
Number of subjects: 46
Study: 38685921

Group type: EXPERIMENTAL
Intervention: Decentralisation of TB diagnostics to primary health centres (PHC) and district hospitals (DH) with a comprehensive diagnosis package including tuberculosis screening, clinical evaluation, Xpert Ultra-testing, and chest radiography.
Number of subjects: 255512

Group type: EXPERIMENTAL
Intervention: Decentralisation in DH-focused districts.
Number of subjects: 255512

Group type: EXPERIMENTAL
Intervention: Decentralisation in PHC-focused districts.
Number of subjects: 255512

Group type: COMPARATOR
Intervention: Pre-intervention period.
Number of subjects: 255512
Study: 38685927

Group type: EXPERIMENTAL
Intervention: iTalkBetter (self-led app utilizing confrontation naming therapy)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: iTalkBetter (self-led app)
Number of subjects: 27
Study: 38685930

Group type: COMPARATOR
Intervention: DH-focused strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: PHC-focused strategy
Number of subjects: 0
Study: 38685972

Group type: EXPERIMENTAL
Intervention: inetetamab and pyrotinib (240 mg, 320 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: inetetamab and pyrotinib
Number of subjects: 48
Study: 38686016

Group type: EXPERIMENTAL
Intervention: Dato-DXd + durvalumab
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Dato-DXd monotherapy
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Investigator's choice of therapy (ICT; capecitabine, pembrolizumab, or capecitabine and pembrolizumab)
Number of subjects: 1075
Study: 38686207

Group type: EXPERIMENTAL
Intervention: Iodine-125 seed implantation
Number of subjects: 36
Study: 38686220

Group type: EXPERIMENTAL
Intervention: Healthy donor stool FMT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (own stool)
Number of subjects: 46
Study: 38686365

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg) administered intravenously post-surgery
Number of subjects: 0
Study: 38686450

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg bd daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 38686621

Group type: EXPERIMENTAL
Intervention: Adaptive Cognitive Training (CT), n = 60, duration: 10 weeks
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Adaptive Cognitive Training (CT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Casual Game Training (active control, AC), n = 64
Number of subjects: 124
Study: 38686814

Group type: EXPERIMENTAL
Intervention: Decrease in extensor strength
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Normalized extensor strength
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Extensor/flexor ratio changes
Number of subjects: 279
Study: 38686863

Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD) defined as index of microcirculatory resistance ≥25 or coronary flow reserve <2.0 with normal fractional flow reserve; measured at 3 months post-STEMI.
Number of subjects: 210

Group type: COMPARATOR
Intervention: No CMD (control group).
Number of subjects: 210
Study: 38686879

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitor initiation
Number of subjects: 66
Study: 38686933

Group type: EXPERIMENTAL
Intervention: EsoCheck/EsoGuard
Number of subjects: 243
Study: 38686961

Group type: EXPERIMENTAL
Intervention: Femoral artery cannulation
Number of subjects: 3751

Group type: COMPARATOR
Intervention: Supra-aortic arterial cannulation
Number of subjects: 3751

Group type: COMPARATOR
Intervention: Direct aortic cannulation
Number of subjects: 3751

Group type: EXPERIMENTAL
Intervention: Switching of the primary site of arterial cannulation
Number of subjects: 3751
Study: 38687061

Group type: EXPERIMENTAL
Intervention: Probiotic intervention (mixture of four probiotic strains with galacto-oligosaccharides) administered to mothers from the 36th week of pregnancy and to infants until 6 months of age.
Number of subjects: 0
Study: 38687136

Group type: EXPERIMENTAL
Intervention: E-cigarette inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38687158

Group type: EXPERIMENTAL
Intervention: immobilization + action observation/mental imagery (AOMI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: immobilization + neuromuscular electrical stimulation (NMES)
Number of subjects: 39

Group type: COMPARATOR
Intervention: immobilization only
Number of subjects: 39

Group type: COMPARATOR
Intervention: control group
Number of subjects: 39
Study: 38687339

Group type: EXPERIMENTAL
Intervention: Direct Cold Atmospheric Plasma treatment, applied once or twice a week
Number of subjects: 0
Study: 38687482

Group type: EXPERIMENTAL
Intervention: Peer-to-peer support intervention
Number of subjects: 2077

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2077
Study: 38687481

Group type: EXPERIMENTAL
Intervention: 0.4-mg aflibercept injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 100
Study: 38687582

Group type: EXPERIMENTAL
Intervention: Digital approaches (such as gamification, photoverification system, and digital media) to generate demand for HIVST and avoid risks associated with attending clinics
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Awareness and sensitization through existing infrastructures (such as churches, schools, and health facilities)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Partnerships with influencers, role models, and leaders (such as religious and youth leaders and social influencers in businesses, churches, organizations, and schools)
Number of subjects: 125